Zhenbaodao released its 2026 interim report, showing first-half operating revenue of 295 million yuan, down 58.6% year on year, while net profit attributable to the parent swung from a loss of 78.29 million yuan in the same period last year to a loss of 271 million yuan. Second-quarter revenue was 114 million yuan, down 53.5% year on year, and the net loss attributable to the parent was 91.03 million yuan, narrowing from a loss of 154 million yuan a year earlier. As of the end of the second quarter, the company's total assets stood at 10.268 billion yuan, down 3.4% from the end of the previous year, and net assets attributable to the parent were 6.011 billion yuan, down 4.3%. The company said that, affected by pharmaceutical sales falling short of expectations, there is a risk of continued decline in revenue and profit, and it is responding by participating in centralized procurement and increasing research and development investment.
Heilongjiang ZBD Pharmaceutical Co LtdFirst-half net loss widened to 271 million yuan from 78.29 million yuan loss a year earlier, with revenue down 58.6%.
